Literature DB >> 1382132

Effect of H1 receptor blockade on the early and late response to cutaneous allergen challenge.

E N Charlesworth1, W A Massey, A Kagey-Sobotka, P S Norman, L M Lichtenstein.   

Abstract

We investigated whether cutaneous antigen-induced inflammatory cell infiltration and mediator release were modified by H1 receptor antagonists. Three chemically unrelated antihistamines (cetirizine, promethazine and chlorpheniramine) were tested in three groups of allergic subjects in a double-blind, crossover design. Chamber fluids were collected for 12 hr and histamine release, prostaglandin D2 production and cellular infiltration were quantified. Cetirizine significantly decreased late leukocyte migration into antigen-challenged chambers: eosinophils by 68% (P less than .04), basophils by 64% (P less than .04) and neutrophils by 72% (P less than .04), whereas mononuclear cells were not significantly affected. No alteration in the numbers of peripheral blood leukocytes or eosinophils occurred while on cetirizine treatment, suggesting that the decrease in inflammatory cells during the late phase reaction in the skin is not secondary to alterations in the peripheral leukocyte pool. In contrast, neither promethazine nor chlorpheniramine induced any significant alteration in inflammatory cell infiltration. All three antihistamines caused significant inhibition of the immediate reaction to antigen without any significant alteration in late phase reaction cutaneous reactivity. None of the three antihistamines caused any significant alteration in histamine or prostaglandin D2 levels. Thus, cetirizine may be an antihistamine uniquely capable of downregulating the late phase reaction inflammatory cell milieu without altering either early or late mediator production. The mechanisms involved and the clinical relevance of these findings remain to be explored.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1382132

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

Review 1.  New insights into the second generation antihistamines.

Authors:  G M Walsh; L Annunziato; N Frossard; K Knol; S Levander; J M Nicolas; M Taglialatela; M D Tharp; J P Tillement; H Timmerman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  In thrombin stimulated human platelets Citalopram, Promethazine, Risperidone, and Ziprasidone, but not Diazepam, may exert their pharmacological effects also through intercalation in membrane phospholipids in a receptor-independent manner.

Authors:  Ramadhan Oruch; Erlend Hodneland; Ian F Pryme; Holm Holmsen
Journal:  J Chem Biol       Date:  2009-04-30

Review 3.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Microvascular mechanisms of histamine-induced potentiation of leukocyte adhesion evoked by chemoattractants.

Authors:  H Thorlacius; J Raud; X Xie; P Hedqvist; L Lindbom
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

Review 5.  Chronic urticaria: background, evaluation, and treatment.

Authors:  E N Charlesworth
Journal:  Curr Allergy Asthma Rep       Date:  2001-07       Impact factor: 4.806

6.  Cetirizine: a review of its use in allergic disorders.

Authors:  Monique P Curran; Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Up-dosing with bilastine results in improved effectiveness in cold contact urticaria.

Authors:  K Krause; A Spohr; T Zuberbier; M K Church; M Maurer
Journal:  Allergy       Date:  2013-06-06       Impact factor: 13.146

Review 8.  Diagnosis and management of rhinitis.

Authors:  D Weldon
Journal:  Prim Care       Date:  1998-12       Impact factor: 2.907

Review 9.  Asthma in children and adolescents: a comprehensive approach to diagnosis and management.

Authors:  Christopher Chang
Journal:  Clin Rev Allergy Immunol       Date:  2012-08       Impact factor: 8.667

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.